A Panel & Holiday Party
Thursday December 13, 2007
• 3:00-3:30 PM Networking & Registration
• 3:30-5:00 PM Investor Panel: "Show Me the Money" Trends in Financing - Looking Back, Looking Ahead
• 5:00-6:30 PM Networking Reception & Champagne Holiday Celebration
Effectively raising capital is crucial for any company. The first key to get funding is to understand where the money is. Join experts from the Investment world to understand the types of financings that are occurring in your industry today– including topics such as who is getting funding, current valuations and other terms, what investors are looking for, etc. – and what is new and what to expect for 2008.
• Nina Kjellson, Partner, InterWest Partners
• Nagesh Mhatre, Partner, The Halo Fund
• Jonathan Norris, Managing Director, Private Equity Group, SVB Capital
• Alex Polinsky, VP and CEO, Pfizer Incubator at Pfizer
• Moderator: Scott M. Iyama, Corporate Lawyer, Member of the Emerging Companies Group, Orrick, Herrington & Sutcliffe LLP
Partner, InterWest Partners
Nina Kjellson focuses primarily on investments in the biopharmaceutical area. She is a board member of Alvine Pharmaceuticals, NovaCardia, Inc. and Trius Therapeutics. Additionally, she is an observer on the boards of AkaRx, Inc., Devax, Inc., Kanisa Pharmaceuticals and MacuSight, Inc. Kjellson also played a primary role in InterWest's investment in Aspreva Pharmaceuticals (Nasdaq: ASPV).
Prior to joining InterWest, Kjellson was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a healthcare-focused hedge fund. Kjellson began her career conducting health policy and survey research with the Kaiser Family Foundation.
Kjellson holds a B.S. in human biology from Stanford University.
A Word from Nina: "I've always known that my career would focus on medicine and the life sciences as I am committed to advancing healthcare technologies and improving access to care. At InterWest, I hope to implement an investment strategy that integrates market vision and technical innovation with sound business planning and leadership. In so doing, it is my objective to partner with the entrepreneurs and scientists working to change the face of healthcare."
Partner, The Halo Fund
Member of The Angels’ Forum
Nagesh S. Mhatre, 74, has over 35 years of senior management experience in international medical technology companies, including Miles Laboratories (Bayer, AG.) and Becton Dickinson & Company. At Becton Dickinson, he served as corporate vice president and president of the company's Immunocytometry Systems Division. Becton Dickinson today is recognized as the leader in the Flow-Cytometry field worldwide. Prior to this, he spent three years as President of Becton Dickinson Laboratory Products, Europe, in Grenoble, France. At Miles Laboratories, he served four years in Rehovot, Israel as managing director of Miles-Yeda, a joint venture with the Weizmann Institute of Science. Under Nagesh’s leadership, Miles-Yeda won an Outstanding Exporter of the State of Israel Award in 1973. Prior to joining the Halo Fund III Management Company, Nagesh has served in the initial development phases as Chairman and CEO (interim) of several startup companies: NuGenesis Technologies Corp., a company that developed and marketed data warehousing and data mining for pharmaceutical research groups; MicroSure, Inc., a medical device company; Strategic Solutions Group, an e-learning company, specializing in systems solutions for training and service for large corporations and US government agencies and Metrika, Inc., a developer of medical diagnostic technologies.
Historically, he also served on the boards of Quidel Corporation, a medical diagnostic company, and NitroMed, Inc., a nitric oxide delivery systems for cardiac stenosis company. Nagesh was founding Chairman of Guava Technologies, Inc. which developed a flow metric system that is the first Personal Cytometer (Guava- PCA) for quantization in the bioanalytical field in human and veterinary sciences. Currently, he serves as founding Chairman of BioImagene Corp, which recently acquired Scimagix, Inc., which he also founded. He served as Executive Chairman of Alpha Innotech Corp., which provides integrated systems tools for functional genomics. He initiated two new startups – Cytoplex Biosciences, Inc., which explores chip technology for cell physiology, and Vista Biosciences, LLC, a developer of a novel continuous glucose monitoring system.
In 2007, Nagesh joined The Halo Fund III Management Company as the Industry Consulting Partner for Medical Technologies. He is also a member of The Angels’ Forum. He serves as a Trustee on the Board of World Affairs Council, San Francisco. He is a Charter Member and was membership chair (1998-1999) of Indus Entrepreneur-TiE Silicon Valley. He has been a member of the Boards of Governors of Silicon Valley Capital Club, Heidelberg International Club, San Francisco, CA. and Friends of Weizmann Institute of Science. Dr. Mhatre received his B.S. degree from Bombay University, India, an M.S. degree from Oregon State University and a Ph.D. degree in biochemistry/microbiology from Rutgers University, New Brunswick, N.J.
Managing Director, Private Equity Group, SVB Capital
Jon Norris is a managing director with SVB Capital's Private Equity Group, specializing in life sciences. Norris has more than seven years of banking experience focused on working with life science companies and venture capital firms. In his current role, Norris is responsible for strengthening relationships with select venture capital firms by leveraging SVB's platform of strategic business units, including investment and commercial banking, as well as global and analytical services.
Prior to joining SVB Capital, Norris was a founding member and senior vice president of Square 1 Bank, where he was an account officer responsible for sourcing deals and managing regional and national venture capital relationships.
Norris also served for more than six years at Imperial Bank (subsequently acquired by Comerica Bank), most recently as senior vice president and group manager of the Northern California Life Science Practice. Prior to banking, Norris was a practicing litigation attorney, specializing in employment defense and toxic tort litigation.
Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.
VP and CEO, The Pfizer Incubator, Pfizer
Alex Polinsky received his Ph.D. in Physical Chemistry from Moscow University in Russia, followed by a post-doctoral training at the Institute of Biochemistry, Russian Academy of Science. He was on faculty at Moscow University for 5 years studying mechanism of action of synthetic vaccines. After moving to the U.S., he spent 2.5 years at UCSD developing methods for computer-aided drug design. In 1991, Alex co-founded Alanex Corporation and served as its Chief Scientific Officer until it was acquired by Agouron in 1997. After acquisition by Pfizer in 2000, Alex became a Vice President, Discovery Technologies in La Jolla Labs. In 2007, Alex established The Pfizer Incubator (TPI) and became its CEO.
Scott M. Iyama
Corporate Lawyer, Member of the Emerging Companies Group, Orrick, Herrington & Sutcliffe LLP
Scott Iyama, a corporate lawyer in Orrick's Silicon Valley office, is a member of the Emerging Companies Group, which advises emerging companies and venture capital firms. Mr. Iyama's practice focuses on the representation of emerging growth life science and high tech companies, as well as public offerings, private venture financings, and technology transactions.
Some of Mr. Iyama’s clients include: AcroMetrix (funded by Telegraph Hill Partners), Facebook (funded by Accel Partners, Greylock, Meritech and Peter Thiel), Greenplum (funded by Sierra, Dawntreader, EDF, Hudson & Mission), Laserscope (acquired by American Medical Systems Holdings), Meebo (funded by Sequoia Capital), Medsphere (funded by Thomas Weisel Venture Partners, Azure Capital, and Wasatch Venture Fund), Micrus Endovascular (NASDAQ: MEND), Sharpcast (funded by Sigma, Selby and Draper Fisher Jurvetson), SquareOne (privately funded), Vendavo (funded by Sigma Partners, Doll Capital Management, InterWest Partners, and others), W5 Networks (funded by Thomas Weisel Venture Partners and U.S. Venture Partners)...
Mr. Iyama has also represented Benchmark Capital, De Novo Ventures, Kleiner Perkins Caufield & Byers, Maveron, Montreux Equity Partners, Telegraph Hill Partners and other venture funds in various investments.
Mr. Iyama frequently lectures on topics related to emerging growth companies at various forums including Stanford Law School and Stanford University.
Prior to receiving his J.D. from Stanford Law School, Mr. Iyama earned a B.S. in Biochemistry and Cell Biology and a M.S. in Biology from the University of California, San Diego. While at the University of California, San Diego, Mr. Iyama performed extensive biochemical research focusing on the general mechanisms governing the initiation of transcription by RNA Polymerase II as well as co-creating the Drosophila Core Promoter Database.